FINEOS-CORPORATION
11.8.2020 02:09:12 CEST | Business Wire | Press release
FINEOS Corporation (ASX:FCL ), the global market leader in core systems for life, accident and health insurance, has entered into an agreement to acquire Limelight Health , a leading North American provider of quoting, rating and underwriting solutions for group and voluntary employee benefits, for $75M US. The union will provide an end-to-end SaaS core product suite from quote, rate and underwrite through to billing, policy administration, absence and claims management for the global life, accident, and health industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200810005814/en/
Michael Kelly , CEO of FINEOS, said: “We’re delighted to welcome the Limelight Health team and their clients to FINEOS, and we look forward to accelerating our combined growth for the benefit of all of our clients, people and partners. This acquisition delivers more product options for our clients as they accelerate their digital transformations and reduce their reliance on legacy core systems. Together we are over 1,000 people with our total focus on helping life, accident, and health carriers to serve their clients and customers with superior insurance technology.”
“The North American employee benefits industry is undergoing tremendous change which is accelerating due to the competitive and regulatory environment as well as the constant advance of technology capabilities,” adds Kelly. “Limelight Health is a rapidly growing Silicon Valley Insurtech with strong roots and competence in the employee benefits industry. They have a collaborative and inclusive culture with a powerful product that has been selected and deployed with leading Tier 1 North American carriers. They are aligned with our FINEOS culture, market focus and technology platform, and we are excited to combine with the Limelight Health team to accelerate our combined growth in North America and globally.”
“This acquisition combines two of the most modern systems in the market today to offer customers a flexible SaaS platform that keeps them future-ready,” said Jason T. Andrew , CEO of Limelight Health. “Joining with FINEOS makes the most of our extensive experience in group benefits and our strong customer base in the US to support our expansion into individual insurance and global markets. Our customers will be able to depend on our combined team with a strong presence in North America, Europe, and Asia. The two companies share similar collaborative values, which will assist us in rapidly and successfully integrating.”
Limelight Health solutions streamline and automate the sales and underwriting functions for group benefits insurers, enabling carriers to win more business with faster, more accurate proposals and an online broker interface. The suite of products for rating, underwriting, and quoting will be available as an optional component of FINEOS AdminSuite , while continuing to be available to the market as a standalone SaaS product solution which readily integrates with third-party and legacy core solutions.
FINEOS and Limelight Health have already built integrations between their products to enable joint go-to-market and system delivery to meet their clients’ needs. This acquisition will enable deeper integration and make it easier to do business with the unified company. The objective is to provide a strong and seamless user experience to everyone inside and outside the carrier’s business operations, making the FINEOS Platform an even more attractive offering to the employee benefits industry.
The transaction is subject to customary closing conditions and is expected to complete quickly. As FINEOS and Limelight Health integrate the business over the coming months, the priority will be to continue to operate on a business as usual basis in order to meet customer needs.
About FINEOS Corporation
FINEOS is a market leader in core systems for life, accident and health insurance carriers globally with 7 of 10 group life and health carriers in the US as well as 6 of the top 10 life and health carriers in Australia. With employees and offices throughout the world, FINEOS continues to scale rapidly, working with innovative progressive carriers in North America, Europe, and Asia Pacific.
The FINEOS Platform, powered by Amazon Web Services , provides customers full end to end core administration for group, voluntary and individual across life, accident and health. The FINEOS Platform includes the FINEOS AdminSuite core product suite as well as add-on products, FINEOS Engage to support digital engagement and FINEOS Insight for analytics and reporting.
For more information, visit www.FINEOS.com .
About Limelight Health
Limelight Health is a leading provider of cloud-based enterprise software solutions delivering the most efficient quoting, rating, and underwriting solutions for employee benefits insurers. The company provides process automation and seamless integration for new business acquisition, including product management, broker self-service, risk management, and sales enablement.
Limelight Health's innovative suite offers highly configurable no-code and low-code solutions for intake, quoting, rating, and underwriting. The API-first and cloud-native architecture provides seamless integration and data exchange for enrollment and case installation, data analysis and reporting, and support for legacy systems. Limelight Health has a remote-first workforce with headquarters in San Francisco, California, and an office in Redding, California.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200810005814/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom